Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Direxion Daily Semiconductor Bull 3X Shares trades at $143.7. The key difference: Direxion Daily Semiconductor Bull 3X Shares is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SOXL | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $491.22 | $300.77 |
52-Week Low | $205.48 | $24.91 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 9.35% to $142.16 amid renewed semiconductor sector optimism. The ETF remains in a technical bearish trend despite the daily rally, with moving averages signaling caution. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the leveraged structure amplifies volatility risks. Financial ratios are unavailable as this is a leveraged ETF tracking semiconductor stocks rather than a traditional company.
SOXL offers aggressive exposure to semiconductor sector rebounds but carries elevated risk due to 3x daily leverage. The current technical setup suggests caution despite positive sentiment around AI chip demand. Key risks include sector volatility, leverage decay, and geopolitical tensions affecting semiconductor supply chains. Investors should understand the specialized nature of leveraged ETFs before considering positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
